ANT-401 / vTv Therapeutics, Aditum Bio - LARVOL DELTA

Aditum Bio Announces Formation of Third Company, Anteris Bio (PRNewswire) - "Aditum Bio...today announced the formation of Anteris Bio, a portfolio company developing a new therapy for the treatment of renal disease. Anteris Bio is being formed following the successful in-licensing of ANT-401 from vTv Therapeutics."

Commercial • Renal Disease

vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio (GlobeNewswire) - "vTv Therapeutics Inc....announced that vTv Therapeutics LLC ('vTv') has entered into a licensing agreement with Anteris Bio for worldwide rights to vTv’s novel clinical-stage Nrf2 activator compound, HPP971. Anteris Bio...will focus on developing HPP971 as a new therapy for the treatment of renal disease....Anteris will pay vTv an upfront payment of $2 million and vTv may be eligible for up to $151 million of future development, regulatory and commercial sales milestones, as well as royalties...HPP971, to be renamed ANT-401, is a small molecule activator of Nrf2..."

Licensing / partnership • Renal Disease